OUR PHILOSOPHY
We develop devices intended to increase the rate of the First Pass Effect underpinned by:
Complete clot ingestion
Improved ease of use
No loss of access
Reduced requirement to bail-out to alternative technologies
Reduced need to combine technologies or use hybrid techniques